Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MLTX 
MoonLake Immunotherapeutics (MLTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MLTX (1-star) is a SELL. SELL since 1 days. Simulated Profits (22.15%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
16 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $76.36
1 Year Target Price $76.36
| 12 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.66% | Avg. Invested days 46 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.38B USD | Price to earnings Ratio - | 1Y Target Price 76.36 |
Price to earnings Ratio - | 1Y Target Price 76.36 | ||
Volume (30-day avg) 16 | Beta 1.27 | 52 Weeks Range 31.42 - 61.87 | Updated Date 09/17/2025 |
52 Weeks Range 31.42 - 61.87 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.99% | Return on Equity (TTM) -40.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3032768670 | Price to Sales(TTM) - |
Enterprise Value 3032768670 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -41.53 | Shares Outstanding 63501400 | Shares Floating 24060046 |
Shares Outstanding 63501400 | Shares Floating 24060046 | ||
Percent Insiders 15.41 | Percent Institutions 94.84 |
Upturn AI SWOT
MoonLake Immunotherapeutics
Company Overview
History and Background
MoonLake Immunotherapeutics was founded in 2021 and is focused on developing and commercializing innovative therapies for immune-mediated inflammatory diseases. The company licensed Sonelokimab from Merck KGaA in 2021 and went public in 2022.
Core Business Areas
- Clinical Development: Focuses on the clinical development of Sonelokimab for various indications.
- Research and Development: Discovery and development of novel therapies for immune-mediated inflammatory diseases.
- Commercialization: Planning and execution of commercialization strategies for approved products.
Leadership and Structure
Dr. Jorge Santos Da Silva is the Chief Executive Officer. The company has a board of directors and a management team focused on clinical development and commercialization.
Top Products and Market Share
Key Offerings
- Sonelokimab: An investigational Nanobodyu00ae targeting IL-17A and IL-17F, under development for the treatment of hidradenitis suppurativa (HS), psoriasis, and psoriatic arthritis (PsA). It is still under clinical trials with no current market share or revenue. Competitors in this space include AbbVie (Humira, Skyrizi), Novartis (Cosentyx), and Eli Lilly (Taltz).
Market Dynamics
Industry Overview
The market for immune-mediated inflammatory disease therapies is large and growing, driven by increasing prevalence and unmet medical needs.
Positioning
MoonLake is positioned as a leader in IL-17A/F inhibition, targeting a broad range of inflammatory diseases. Its competitive advantage lies in Sonelokimab's potential best-in-class efficacy.
Total Addressable Market (TAM)
The TAM for IL-17 inhibitors in indications like HS, psoriasis, and PsA is estimated to be in the billions of dollars annually. MoonLake is positioned to capture a significant share of this market if Sonelokimab receives regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel IL-17A/F Nanobodyu00ae with potential for superior efficacy
- Experienced management team
- Strong clinical trial results (early stage)
- Focused on large and growing market segments
Weaknesses
- Single product focus (Sonelokimab)
- No approved products and dependent on clinical trial success
- Reliance on funding for clinical development
- Relatively new company with limited commercial experience
Opportunities
- Expansion of Sonelokimab into additional indications
- Potential for partnerships and collaborations
- Positive clinical trial results driving market value
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent challenges
- Generic erosion post approval of new products
Competitors and Market Share
Key Competitors
- ABBV
- NVS
- LLY
Competitive Landscape
MoonLake faces competition from established pharmaceutical companies with marketed products for immune-mediated inflammatory diseases. Its competitive advantage hinges on the potential for Sonelokimab to offer superior efficacy and convenience.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in increasing R&D spending and expansion of clinical programs.
Future Projections: Future growth is dependent on the successful development and commercialization of Sonelokimab. Analyst estimates vary based on clinical trial outcomes and market penetration assumptions.
Recent Initiatives: Advancement of Sonelokimab through Phase 2 and Phase 3 clinical trials, and exploration of new indications.
Summary
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company with a promising lead product candidate, Sonelokimab, targeting IL-17A/F. The company is financially stable and continues to develop its novel therapy for multiple indications. Successful clinical trials and regulatory approvals are essential for its growth; it faces intense competition from established players. A key risk is clinical trial failure, which would heavily impact its future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MoonLake Immunotherapeutics Investor Relations
- Company SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual financial circumstances and after consulting with a qualified financial advisor. Market share data are estimates based on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MoonLake Immunotherapeutics
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-10-20 | Co-Founder, CEO & Director Dr. Jorge Santos da Silva Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 100 | Website https://www.moonlaketx.com |
Full time employees 100 | Website https://www.moonlaketx.com | ||
MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.